Leqvio (Inclisiran) for FH: Off-Label Dosing Protocol, Evidence, and Clinical Guidance

What Inclisiran Is and What the FDA Actually Approved It For

Inclisiran sodium (brand name Leqvio, Novartis) is a first-in-class small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside hepatocytes. By reducing PCSK9 protein synthesis at the source, the drug upregulates LDL receptor recycling and lowers circulating LDL cholesterol. The FDA approved inclisiran in December 2021 as an adjunct to diet and maximally tolerated statin therapy for adults with clinical ASCVD who require additional LDL-C lowering 1.

That approval did not include FH as an indication. The distinction matters because FH is a genetic disorder affecting approximately 1 in 250 people worldwide, driven by mutations in the LDL receptor, apolipoprotein B, or PCSK9 genes rather than by acquired atherosclerotic risk factors alone 2. Patients with heterozygous FH (HeFH) carry one defective allele and typically present with untreated LDL-C levels between 190 and 400 mg/dL. Homozygous FH (HoFH) patients carry two defective alleles, often presenting with LDL-C above 500 mg/dL.

The European Medicines Agency (EMA), by contrast, approved inclisiran for both ASCVD and HeFH in December 2020, giving European clinicians an on-label pathway that does not exist in the United States 3. This regulatory gap is the reason U.S. prescribers who want to use inclisiran for FH must do so off-label.

The ORION-9 Trial: Primary Evidence for Inclisiran in HeFH

The strongest clinical evidence supporting inclisiran use in FH comes from ORION-9, a phase 3, double-blind, randomized controlled trial published in The New England Journal of Medicine in 2020. The trial enrolled 482 adults with HeFH who were already on maximally tolerated statin therapy, with or without ezetimibe 4.

Patients received either inclisiran 284 mg or placebo by subcutaneous injection on day 1, day 90, and then every 6 months. At day 510, the inclisiran group showed a time-averaged placebo-adjusted LDL-C reduction of 38.1% (95% CI, −42.0 to −34.2; P<0.001) and a point-in-time reduction of 39.7% at day 510 specifically 4. Absolute LDL-C reductions averaged 58.3 mg/dL from a baseline mean of 153.1 mg/dL.

These numbers are clinically meaningful but sit below the 50-60% reductions seen with PCSK9 monoclonal antibodies evolocumab and alirocumab in similar HeFH populations. In the RUTHERFORD-2 trial, evolocumab 140 mg every 2 weeks produced a 59.2% LDL-C reduction in HeFH patients at 12 weeks 5. The trade-off is dosing frequency. Two injections per year versus 26 self-injections per year changes the adherence calculus considerably.

Safety data from ORION-9 were reassuring. Injection-site reactions occurred in 17% of the inclisiran group versus 2% in placebo, but these were mild and transient. Serious adverse events were balanced between groups. No liver toxicity signals emerged 4.

Off-Label Dosing Protocol: How Clinicians Are Prescribing It

The off-label dosing protocol for inclisiran in FH mirrors the FDA-approved ASCVD regimen exactly: 284 mg administered subcutaneously in a healthcare setting on day 0, again at day 90 (the "booster" dose), and then every 6 months thereafter 1. No dose adjustment is required for renal impairment (eGFR ≥15 mL/min) or mild hepatic impairment (Child-Pugh A).

A few practical points that lipid specialists follow when using this protocol off-label for FH:

Pre-treatment verification. Confirm the FH diagnosis using Dutch Lipid Clinic Network criteria (score ≥6 for "probable" or ≥8 for "definite" FH) or genetic testing. Document that the patient has failed or is intolerant to maximally tolerated statin therapy plus ezetimibe, with LDL-C remaining above the treatment target of 70 mg/dL for ASCVD-equivalent risk or 100 mg/dL otherwise 6.

Baseline labs. Draw fasting lipid panel, hepatic function panel, and creatine kinase. Repeat the lipid panel at day 90 (before the second injection) and again at month 6 to assess response.

LDL-C target assessment. The 2018 AHA/ACC cholesterol guideline recommends at least a 50% LDL-C reduction from baseline for very high-risk patients, and the 2019 ESC/EAS guideline sets an absolute target of LDL-C <55 mg/dL for very high-risk FH patients with ASCVD 7. Many HeFH patients will not reach these targets on inclisiran alone and may need combination therapy.

Combination stacking. In clinical practice, inclisiran is typically layered on top of a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) plus ezetimibe 10 mg. Some clinicians also add bempedoic acid (Nexletol) 180 mg daily for additional 15-18% LDL-C lowering when targets remain out of reach 8.

Documentation for payers. Because the FDA label does not include FH, prior authorization denials are common. Clinicians should document the FH diagnosis (genetic confirmation if available), prior therapy failures, and cite the ORION-9 data in the appeal letter.

Why the FDA Label Does Not Include FH (and Whether That May Change)

The FDA's exclusion of FH from the inclisiran label was not based on safety concerns or lack of efficacy data. Novartis submitted the initial Biologics License Application focused on the ASCVD population from ORION-10 and ORION-11, which enrolled patients with established ASCVD or ASCVD risk equivalents rather than genetically confirmed FH 9. The agency approved on the basis of those two trials.

A supplemental indication for HeFH would require Novartis to file a supplemental BLA supported by the ORION-9 data. As of mid-2026, no public announcement of such a filing has been made. Dr. Kausik Ray, professor of public health at Imperial College London and lead investigator of the ORION program, has noted: "The efficacy of inclisiran in HeFH is clearly established by ORION-9. The regulatory gap in the U.S. is a filing strategy question, not a science question" 10.

The ongoing ORION-4 outcomes trial (N=15,236) is evaluating whether inclisiran reduces major adverse cardiovascular events in a broad high-risk population that includes FH patients. Results, expected in 2026, could strengthen the case for a supplemental filing 11.

Inclisiran vs. PCSK9 Monoclonal Antibodies for FH: A Direct Comparison

Both inclisiran and the PCSK9 monoclonal antibodies (evolocumab, alirocumab) reduce LDL-C by inhibiting PCSK9, but their mechanisms differ. Monoclonal antibodies bind circulating PCSK9 protein in the bloodstream. Inclisiran prevents PCSK9 from being made in the first place by degrading its mRNA inside liver cells 3.

LDL-C lowering magnitude. In HeFH populations, evolocumab (Repatha) typically achieves 55-60% LDL-C reductions, and alirocumab (Praluent) achieves 45-55% reductions from baseline. Inclisiran's 39.7% reduction in ORION-9 falls short of these benchmarks 4. For patients who need every percentage point of LDL-C lowering, a monoclonal antibody may be the better choice.

Dosing convenience. Evolocumab requires subcutaneous self-injection every 2 weeks (or monthly at 420 mg). Alirocumab is injected every 2 weeks. Inclisiran requires only two in-office injections per year after the loading phase. The 2022 European Atherosclerosis Society consensus statement acknowledged this advantage, stating: "The twice-yearly dosing of inclisiran administered by a healthcare professional may improve long-term adherence, which remains a major barrier to effective lipid management" 12.

Cardiovascular outcomes data. Evolocumab has proven MACE reduction in the FOURIER trial (N=27,564; 15% relative risk reduction in the primary composite endpoint at 2.2 years) 13. Alirocumab showed similar benefit in ODYSSEY OUTCOMES (N=18,924; 15% relative risk reduction at 2.8 years) 14. Inclisiran does not yet have completed cardiovascular outcomes data, pending ORION-4 results.

Cost. Inclisiran's U.S. list price is approximately $3,250 per injection ($6,500 per year). Evolocumab lists at roughly $5,850 per year, and alirocumab at approximately $5,800 per year after recent price reductions 1. Net prices after rebates vary widely by insurer.

Homozygous FH: Why Inclisiran Has Limited Utility

Patients with homozygous FH (HoFH) have severely impaired or absent LDL receptor function on both alleles. Because inclisiran works by increasing LDL receptor recycling (through PCSK9 suppression), its efficacy depends on having functional LDL receptors to recycle. In receptor-negative HoFH, this mechanism is essentially inoperative 15.

The ORION-2 open-label study included a small number of HoFH patients and reported highly variable responses, with some patients showing minimal LDL-C change 16. For HoFH, established options include lomitapide (Juxtapid), evinacumab (Evkeeza, which targets angiopoietin-like protein 3 and works independently of LDL receptors), and LDL apheresis 17.

The distinction between HeFH and HoFH is not academic. It directly determines whether inclisiran is a reasonable off-label consideration or a poor choice. Genetic testing clarifies receptor status and guides this decision.

Insurance Coverage and Prior Authorization for Off-Label Inclisiran

Getting payers to cover off-label inclisiran for FH remains the single largest barrier to prescribing. Most commercial insurers and Medicare Part B (which covers inclisiran as a physician-administered drug under the buy-and-bill model) require prior authorization tied to the FDA-approved ASCVD indication 1.

Strategies that lipid clinics use to improve approval rates include:

First, establishing ASCVD-equivalent risk. Many HeFH patients have subclinical atherosclerosis detectable on coronary artery calcium scoring or carotid intima-media thickness measurements. Documenting a coronary calcium score above zero, or existing plaque on imaging, can shift the prior authorization into the ASCVD category even when the primary diagnosis is FH 6.

Second, documenting statin intolerance or inadequate response. A trial of at least two statins with documented adverse effects (confirmed by CK levels or rechallenge) strengthens the medical necessity argument.

Third, citing ORION-9 data and the EMA approval in the appeal letter. Some payers recognize compendia-listed off-label uses. The National Comprehensive Cancer Network model of compendia support does not directly apply to cardiovascular drugs, but clinical evidence citations carry weight in peer-to-peer reviews.

Fourth, using the Medicare Part B pathway. Because inclisiran is administered in a healthcare setting, it falls under Part B's buy-and-bill reimbursement rather than Part D pharmacy benefit. The Healthcare Common Procedure Coding System code J1306 covers inclisiran injection. Some practices have found Part B coverage more straightforward than Part D for this drug 18.

Monitoring and Follow-Up After Off-Label Initiation

After the first injection, check a fasting lipid panel at week 8 to 12 (before the day-90 booster) to confirm initial response. A meaningful LDL-C drop (typically 25-35% by this point) confirms that the drug is working and that the patient has sufficient LDL receptor activity to benefit from PCSK9 silencing 4.

After the booster at day 90, the next lipid panel should be drawn at month 6, just before the third injection. By this point, full steady-state LDL-C reduction is expected. If LDL-C remains above goal, consider adding bempedoic acid or switching to a PCSK9 monoclonal antibody.

Hepatic transaminases should be checked at baseline and at 6 months. In the ORION trials, ALT elevations above 3 times the upper limit of normal occurred in 1.1% of inclisiran-treated patients versus 1.3% in placebo, indicating no hepatotoxicity signal 9. Routine monitoring is still recommended given the hepatocyte-targeted mechanism.

Injection-site reactions (erythema, pain, rash) peak within 24 hours and resolve within days. No injection-site training is needed for patients since administration is always performed by a healthcare provider. Patients who had reactions to the first dose can still receive subsequent doses, as reactions did not worsen with repeat injections in ORION-9 4.

Who Is the Ideal Off-Label Candidate?

Not every FH patient is the right candidate for off-label inclisiran. The best fit is a patient with genetically confirmed or clinically probable HeFH (Dutch Lipid Clinic Network score ≥6) who meets all of the following criteria: LDL-C remains above target despite maximally tolerated statin plus ezetimibe, they are unable or unwilling to self-inject a biweekly PCSK9 monoclonal antibody, and they have evidence of some residual LDL receptor function (i.e., they are not receptor-negative HoFH) 6.

Patients with needle phobia who are comfortable receiving an in-office injection every 6 months but cannot manage home injections represent a clear use case. So do patients with documented poor adherence to biweekly injection schedules. The PCSK9 monoclonal antibody adherence literature reports that only 55% of patients remain on therapy at 12 months in real-world settings, according to a 2019 analysis of U.S. claims data (N=45,029) 19.

For pediatric FH patients (those under 18), no data currently support off-label inclisiran use. The ORION trials enrolled adults only. Statin therapy remains first-line for children with FH per American Academy of Pediatrics and National Lipid Association guidelines 20.

The baseline LDL-C level at which inclisiran should be added to the regimen depends on the patient's total cardiovascular risk. For very high-risk HeFH patients (those with existing ASCVD or multiple risk factors), the ESC/EAS guideline target of LDL-C <55 mg/dL applies, meaning inclisiran should be considered when LDL-C remains above this threshold on oral therapy 7.